Bandi Parthasaradhi Reddy – Chairman & Managing Director, Hetero…
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Address: HETERO DRUGS LIMITED, 7-2-A2, HETERO CORPORATE, INDUSTRIAL ESTATES. SANATH NAGAR, HYDERABAD – 500 018. A.P. INDIA
,India
Tel: +91 40 23704923
Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.
Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization. Hetero is a leading international supplier with a rich portfolio of over 200 products from wide range of therapeutic categories both in active pharmaceutical ingredients and finished dosages.
Hetero’s manufacturing facilities are cGMP compliant meeting global standards in terms of infrastructure and systems. Majority of them are approved by the various regulatory authorities of USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines & health care products, ANVISA-Brazil, IDA-Netherlands etc.,
With full-fledged marketing capabilities, the company has been able to market its products in over 138 countries across the globe.
APIs
Hetero is one of the largest manufacturer and supplier of Active Pharmaceutical Ingredients (API’s) catering to the ever increasing requirements of the global pharmaceutical market.
The infrastructure available with Hetero for manufacturing of Active Pharmaceutical Ingredients and the intermediate chemicals is one of the best, with State-of-the- Art facilities designed to meet the global standards and cGMPs.
With 11 API manufacturing facilities in operation, Hetero has been able to manufacture more than 200 APIs, and supply to different markets. 6 of the API facilities are approved by USFDA, TGA, EU, PMDA, KFDA and WHO.
Hetero is a trusted supplier of several APIs in wide range of therapeutic categories and the largest supplier of complete range in Antiretroviral products.
Hetero also has dedicated facility for manufacturing of Oncology products.
FINISHED DOSAGES
Hetero has world-class facilities for manufacturing wide range of finished dosages.
As a leading innovation-driven corporation, Hetero is developing a growing portfolio of pharmaceutical products to meet some of the world’s most urgent medical needs. Today Hetero is manufacturing product portfolio of over 200 products in major therapeutic areas, with an emphasis on antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, antidiabetics, pain management, anti-infectives, dermatology and oncology. Hetero has
Four finished dosage manufacturing facilities, out of which two are USFDA approved facilities.
Dedicated Oncology facility
Offers
Injectables
Solid/Liquid oral dosages
Ointments
Soft gelatine capsules
Inhalers
INTERMEDIATE CHEMICALS
For information on intermediate chemicals please contact:
uma@heterodrugs.com
contact@heterodrugs.com
CRAMS
Hetero initiated customer-centric division that will provide Custom Research And Manufacturing Services (CRAMS) for large, mid-sized and emerging biotech and pharmaceutical entities globally.
Hetero will partner with these companies and cultivate opportunities to research, manufacture and develop compounds across the entire drug life cycle. This division will deliver fully-consolidated or customized manufacturing solutions for APIs, intermediate chemicals, pre-formulations and formulations across each stage of the pharmaceutical life cycle. Hetero provides premium solutions for product life cycle management including life cycle extensions and line extensions.
BIOTECHNOLOGY
Hetero is focusing on the development and manufacturing of bio-generics for domestic and international markets.
Product Pipeline
Five biosimilars are in the various stages of development. Two products are expected to be commercialized in India for oncology and nephrology indications by 2011-12.
DRUG DISCOVERY
Hetero started discovery research with the focus on developing NCEs in selected therapeutic areas. Scientists at Drug Discovery Division are working on the following projects :
ANTI-HIV Research
ANTI-HCV Research
Diabetes Research
Our business strategy is to out licence early stage discovery molecules and to explore early stage discovery collaborations to maximize the potential of our discovery projects.
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Dr. Letitia Robinson, Director of the US FDA India Office, provides insights into the main goals and responsibilities of the FDA in India and documents the US FDA’s collaboration efforts…
Dr. Deepak Birewar, founder and chairman of the dynamically growing CDMO Inventys Research, highlights the crucial importance of innovation in the company’s strategy to outperform its competition and strengthen its…
VS Reddy, fondly known as ‘The Protein Man of India’ and founder and managing director of British Biologicals, India’s leading nutraceutical company, provides insights into the pioneering role played by…
Jonathan Hunt, CEO of Syngene International, one of the fastest-growing and leading contract research and manufacturing organizations in the world, discusses the company’s unique ecosystem of innovation, India’s eye-catching talent…
Nitin Shah, founder and chairman of Unison Pharmaceuticals Pvt. Ltd., and Bhagyesh Shah, managing director, provide insights into the unique positioning of this eye-catching company, which has forged a great…
RS Raghav, founder and managing director of Oaknet Healthcare, documents the key fundamentals that have enabled Oaknet to proudly become a Top 100 player in the competitive Indian market within…
Mohal Sarabhai, a serial entrepreneur and grandson of the illustrious scientist and industrialist Vikram Sarabhai, provides insights into the eye-catching group of companies he has been developing over the past…
Vivek Sharma, CEO of Piramal Pharma Solutions (PPS), one of the world’s leading CDMOs with a presence in North America, Europe, and Asia, provides insights into the main trends shaping…
Swati Jajodia, managing director of Swati Spentose discusses her commitment to tackling underserved diseases and the company’s approach to bringing pentosan polysulfate to global markets while working with Key Opinion…
Jai and Sameer Hiremath of Hikal provide insights into the main trends shaping the Indian and global CDMO industry. They articulate how Hikal’s long-standing focus on quality standards, regulatory compliance,…
Dr. Hemant Koshia, commissioner of the FDCA Gujarat, the regulatory authority of the state of Gujarat – India’s leading hub for the production of pharmaceutical and healthcare products – provides…
Dr. Georges Jabre, the recently appointed CEO of Serdia Pharmaceuticals (India) Pvt. Ltd. (an affiliate of the Servier Group) and president of the Healthcare Committee of the Indo-French Chamber of…
See our Cookie Privacy Policy Here
